Glucocorticoid 16alpha, 17.alpha.-isoxazolidines as antiinflammatory agents

Details for Australian Patent Application No. 2005261869 (hide)

Owner Novartis AG

Inventors Watson, Simon James; Sandham, David Andrew; Sharp, Christopher William

Agent Davies Collison Cave

Pub. Number AU-B-2005261869

PCT Pub. Number WO2006/005611

Priority 0415747.5 14.07.04 GB

Filing date 13 July 2005

Wipo publication date 19 January 2006

Acceptance publication date 19 March 2009

International Classifications

C07J 71/00 (2006.01) Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring

A61K 31/58 (2006.01) - containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin

A61P 5/44 (2006.01) Drugs for disorders of the endocrine system

Event Publications

1 February 2007 PCT application entered the National Phase

  PCT publication WO2006/005611 Priority application(s): WO2006/005611

19 March 2009 Application Accepted

  Published as AU-B-2005261869

16 July 2009 Standard Patent Sealed

9 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005261870-Device and method for analysis of interactions between biomolecules

2005261868-Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)